Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Toward targeting the untargetable: A non-canonical EGFR-peptide-drug conjugate achieves potent antitumor activity in KRAS-mutant CRC.

Journal of controlled release : official journal of the Controlled Release Society - 10 Jul 2026

Ayali Shachar, Panja Akash, Mitra Pousali, Dutta Gupta Yashaswi, Tobi Dror, Bazylevich Andrii, Brenner Baruch, Cohen Zoya, Ayale Ayelet Rosenberg, Nesher Elimelech, Gellerman Gary, Lubin Bat Chen R

Abstract excerpt

Colorectal cancer (CRC) harboring KRAS mutations remains a major therapeutic challenge, as resistance to EGFR directed signaling inhibitors persists despite receptor expression. We aimed to establish a delivery-based therapeutic strategy that bypasses EGFR signaling inhibition by exploiting the receptor as an internalization gate. We report the development of a peptide-drug conjugate (PDC) that exploits...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Camptothecin
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Irinotecan

Share to Mice, Nude

Share to Peptides

Share to Proto-Oncogene Proteins p21(ras)

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 42103029
DOI: 10.1016/j.jconrel.2026.114993

Genes

EGFR
KRAS
PDC
EGF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Toward targeting the untargetable: A non-canonical EGFR-peptide-drug conjugate achieves potent antitumor activity in KRAS-mutant CRC.PMID 42103029Read ↗

Potency and selectivity of a novel pan-RAS inhibitor in 3D bioprinted organoid tumor modelsSemantic proximity Read ↗

Nanoformulation of the K-Ras(G12D)-inhibitory peptide KS-58 suppresses colorectal and pancreatic cancer-derived tumors.Semantic proximity Read ↗

Enhanced Efficacy of EGFR-Targeted ADCs via p38-Mediated Noncanonical Endocytosis in EGFR-Mutant Lung Cancer Cells.Semantic proximity Read ↗

Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance.Semantic proximity Read ↗

Discovery of cell active macrocyclic peptides with on-target inhibition of KRAS signalingSemantic proximity Read ↗

The K-Ras(G12D)-inhibitory peptide KS-58 suppresses growth of murine CT26 colorectal cancer cell-derived tumors.Semantic proximity Read ↗

The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced ResistanceSemantic proximity Read ↗

Ferritin-based nanocarrier delivery of KRAS G12D inhibitor in pancreatic adenocarcinoma cells and patient-derived organoids: A novel approach for treatment.Semantic proximity Read ↗

Multi-targeting of K-Ras domains and mutations by peptide and small molecule inhibitors.Semantic proximity Read ↗

Effective Degradation of Wild-Type and Mutant EGFR Using Self-Assembling Peptide-Derived PROTAC Nanoparticles (NanoTACs) for Cancer Therapy.Semantic proximity Read ↗

Cetuximab increases LGR5 expression and augments LGR5-targeting antibody-drug conjugate efficacy in patient-derived colorectal cancer modelsSemantic proximity Read ↗

α4-α5 Helices on Surface of KRAS Can Accommodate Small Compounds That Increase KRAS Signaling While Inducing CRC Cell Death.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.